<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt">UNITED STATES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt">SECURITIES
AND EXCHANGE COMMISSION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt">CURRENT REPORT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section&nbsp;13 or 15(d) of
the Securities Exchange Act of 1934</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Date of Report (Date of Earliest Event Reported): </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March 7, 2014</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 24pt">Marina Biotech,
Inc. </FONT>
</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 35%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">

<FONT STYLE="font-size: 10pt">(Exact name of registrant as specified in its charter) </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Delaware </FONT></TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 29%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">000-13789 </FONT></TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 29%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">11-2658569 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; vertical-align: top">
    <FONT STYLE="font-size: 10pt">(State or other jurisdiction </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">
    <FONT STYLE="font-size: 10pt">(Commission </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">
    <FONT STYLE="font-size: 10pt">(I.R.S. Employer </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">of incorporation) </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">File Number) </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Identification No.) </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">P.O. Box 1559 , Bothell, WA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">98041 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; vertical-align: top">
    <FONT STYLE="font-size: 10pt">(Address of principal executive offices) </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">
    <FONT STYLE="font-size: 10pt">(Zip Code) </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Registrant&rsquo;s telephone number, including area code: </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">425-892-4322 </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Former name or former address, if changed since last report</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 1.01 Entry Into a Material Definitive Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">On March
7, 2014, Marina Biotech, Inc. (the &ldquo;<U>Company</U>&rdquo;) entered into a Securities Purchase Agreement (the &ldquo;<U>Purchase
Agreement</U>&rdquo;) with certain qualified investors identified on the signature pages thereto (the &ldquo;<U>Investors</U>&rdquo;),
led by Steven T. Newby, a long-time biotechnology investor, pursuant to which the Company issued to the Investors 1,200 shares
of the Company&rsquo;s Series C Convertible Preferred Stock (the &ldquo;<U>Preferred Shares</U>&rdquo;) and warrants (the &ldquo;<U>Warrants</U>&rdquo;)
to purchase up to 6,000,000 shares of the Company&rsquo;s common stock (&ldquo;<U>Common Stock</U>&rdquo;) for an aggregate purchase
price of $6 million. The Preferred Shares are convertible into Common Stock at a conversion price of $0.75 per share of Common
Stock. The Warrants have an exercise price of $0.75 per share of Common Stock and are exercisable for a period of five (5) years
after the Company regains compliance with its reporting obligations under the Securities Exchange Act of 1934, as amended. The
Company and the Investors entered into the Purchase Agreement in accordance with that certain binding term sheet dated February
23, 2014. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">The
foregoing summary does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement and
the Form of Warrant, a copy of each of which is attached as an exhibit to this Current Report on Form 8-K and incorporated herein
by reference.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 3.02 Unregistered Sales of Equity Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">Pursuant
to the Purchase Agreement and the transactions contemplated thereby described in Item 1.01 above, the Company issued the Preferred
Shares and the Warrants to the Investors. The Company issued such securities in reliance on the exemption contained in Section
4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 3.03 Material Modification to Rights of Security
Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">A total
of 1,200 shares of Series C Convertible Preferred Stock (the &ldquo;<U>Series C Preferred Stock</U>&rdquo;) have been authorized
for issuance under the Certificate of Designation of Rights, Preferences and Privileges of Series C Convertible Preferred Stock
(the &ldquo;<U>Certificate of Designation</U>&rdquo;). The Company filed the Certificate of Designation with the Secretary of
State of the State of Delaware on March 7, 2014. The shares of Series C Preferred Stock have a stated value of $5,000 per share
and are initially convertible into shares of Common Stock at a price of $0.75 per share (subject to appropriate adjustment for
certain events, including stock splits, stock dividends, combinations, recapitalizations or other recapitalizations affecting
the Series C Preferred Stock). Under the Certificate of Designation, the holders of the Series C Preferred Stock have the following
rights, preferences and privileges:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">The
Series C Preferred Stock may, at the option of the Investor, be converted at any time or from time to time into fully paid and
non-assessable shares of Common Stock at the conversion price in effect at the time of conversion. The number of shares into which
one share of Series C Preferred Stock shall be convertible is determined by dividing the stated value per share by the initial
Conversion Price. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">The
Series C Preferred Stock will automatically be converted into Common Stock at the then applicable conversion Price upon the earliest
to occur of: (a) the written election of Investors holding at a majority of Series C Preferred Stock; (b) at the election of the
Company, the closing of a &ldquo;Qualified Acquisition&rdquo; (as defined in the Certificate of Designation); (c) at the election
of the Company, the closing of a bona-fide strategic financing by the Corporation yielding gross proceeds to the Corporation of
not less than $12 million (a &ldquo;<U>Qualified Financing</U>&rdquo;); or (d) at the election of the Company, the date on which
the Common Stock commences trading on a national securities exchange. Investors holding a majority of Series C Preferred Stock
will also have the right to convert the outstanding Series C Preferred Stock into such number or amount of the securities of the
Company that are issued upon the closing of a Qualified Financing that occurs on or prior to the one-year anniversary of the first
date following the filing of the Certificate of Designation on which the Company is current with respect to the filing of all
reports required to be filed by it pursuant to Sections 13 or 15(d) of the Exchange Act (other than Form 8-K reports) as have
a purchase price equal to the stated value of the outstanding shares of Series C Preferred Stock, plus any accrued and unpaid
dividends thereon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">On
any matter presented to the holders of Common Stock for their action or consideration, each holder of outstanding shares of Series
C Preferred Stock shall be entitled to vote together with the holders of Common Stock as a single class on an as-converted basis.
In addition, for as long as any shares of Series C Preferred Stock are outstanding, the Company shall not, without the affirmative
vote of Investors holding at least a majority of the Series C Preferred Stock: (a) alter or change adversely the powers, preferences
or rights given to the Series C Preferred Stock or alter or amend the Certificate of Designation; (b) authorize or create any
class of stock ranking senior to, or otherwise pari passu with, the Series C Preferred Stock; (c) amend its organizational documents
in any manner that adversely affects any rights of the Series C Preferred Stock; (d) increase the number of authorized shares
of Series C Preferred Stock; or (e) enter into any agreement with respect to any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">In the
event of any voluntary or involuntary liquidation or dissolution of the Company, before any payment shall be made to the holders
of Common Stock, the holders of shares of Series C Preferred Stock then outstanding shall be entitled to be paid an amount per
share of Series C Preferred Stock equal to the greater of (a) the stated value for such share of Series C Preferred Stock, plus
any dividends declared but unpaid thereon, or (b) the amount as would have been payable had such share of Series C Preferred Stock
been converted into Common Stock immediately prior to such liquidation or dissolution. The remaining funds shall be distributed
to the holders of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">The
Company may not declare, pay or set aside any dividends on shares of any class or series of capital stock of the Company (other
than dividends on shares of Common Stock payable in shares of Common Stock) unless the holders of the Series C Preferred Stock
shall first receive, or simultaneously receive, an equal dividend on each outstanding share of Series C Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 5.03 Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">The
disclosures set forth in Items 1.01 and 3.03 of this Current Report on Form 8-K are hereby incorporated by reference into this
Item 5.03.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01 Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Press Release</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 11, 2014, the Company issued
a press release announcing that it had entered into, and consummated the transactions contemplated by, the Purchase Agreement.
A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Investor Presentation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 11, 2014, the Company presented
at the BIO-Europe Spring&reg; 2014 partnering conference. A copy of the presentation is attached as Exhibit 99.2 to this Current
Report on Form 8-K and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 9.01 Financial Statements and Exhibits.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">(d) Exhibits:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 10%; font-weight: bold; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Exhibit No.</FONT></TD>
    <TD NOWRAP STYLE="width: 5%; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 85%; font-weight: bold; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Description</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-weight: normal">3.1</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-weight: normal">Certificate of Designation of Rights,
    Preferences and Privileges of Series C Convertible Preferred Stock.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-weight: normal">4.1</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-weight: normal">Form of Common Stock Purchase Warrant.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-weight: normal">10.1</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-weight: normal">Securities Purchase Agreement dated as of March 7, 2014 between
    and among the Company and each purchaser identified on the signature pages thereto.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; font-weight: bold"><FONT STYLE="font-weight: normal">99.1</FONT></TD>
    <TD STYLE="width: 5%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 85%; font-weight: bold"><FONT STYLE="font-weight: normal">Press release of Marina Biotech, Inc. dated March
    11, 2014.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-weight: normal">99.2</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-weight: normal">Investor Presentation of Marina Biotech, Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">__________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Marina Biotech, Inc.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 32%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 10, 2014</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ J. Michael French</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="width: 49%">&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">J. Michael French</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD>&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>EXHIBIT INDEX</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 10%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>Exhibit No.</B></FONT></TD>
    <TD NOWRAP STYLE="width: 4%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP STYLE="width: 86%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-weight: normal">3.1</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-weight: normal">Certificate of Designation of Rights,
    Preferences and Privileges of Series C Convertible Preferred Stock.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-weight: normal">4.1</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-weight: normal">Form of Common Stock Purchase Warrant.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-weight: normal">10.1</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-weight: normal">Securities Purchase Agreement dated as of March 7, 2014 between
    and among the Company and each purchaser identified on the signature pages thereto.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-weight: normal">99.1</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-weight: normal">Press release of Marina Biotech, Inc. dated March 11, 2014.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-weight: normal">99.2</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-weight: normal">Investor Presentation of Marina Biotech, Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">__________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "t1400387_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 33620}]
{"company-data": {"conformed-name": "Marina Biotech, Inc.", "cik": "0000737207", "assigned-sic": "2834", "irs-number": "112658569", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-13789", "film-number": "14683082"}, "business-address": {"street1": "3830 MONTE VILLA PARKWAY", "city": "BOTHELL", "state": "WA", "zip": "98021", "phone": "4259083600"}, "mail-address": {"street1": "3830 MONTE VILLA PARKWAY", "city": "BOTHELL", "state": "WA", "zip": "98021"}, "former-company": [{"former-conformed-name": "MDRNA, Inc.", "date-changed": "20080610"}, {"former-conformed-name": "NASTECH PHARMACEUTICAL CO INC", "date-changed": "19920703"}]}
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
March 7, 2014
Marina Biotech,
Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-13789
11-2658569
(State or other jurisdiction
(Commission
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
P.O. Box 1559 , Bothell, WA
98041
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
425-892-4322
N/A
Former name or former address, if changed since last report
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
¨
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry Into a Material Definitive Agreement.
On March
7, 2014, Marina Biotech, Inc. (the "
Company
") entered into a Securities Purchase Agreement (the "
Purchase
Agreement
") with certain qualified investors identified on the signature pages thereto (the "
Investors
"),
led by Steven T. Newby, a long-time biotechnology investor, pursuant to which the Company issued to the Investors 1,200 shares
of the Company's Series C Convertible Preferred Stock (the "
Preferred Shares
") and warrants (the "
Warrants
")
to purchase up to 6,000,000 shares of the Company's common stock ("
Common Stock
") for an aggregate purchase
price of $6 million. The Preferred Shares are convertible into Common Stock at a conversion price of $0.75 per share of Common
Stock. The Warrants have an exercise price of $0.75 per share of Common Stock and are exercisable for a period of five (5) years
after the Company regains compliance with its reporting obligations under the Securities Exchange Act of 1934, as amended. The
Company and the Investors entered into the Purchase Agreement in accordance with that certain binding term sheet dated February
23, 2014.
The
foregoing summary does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement and
the Form of Warrant, a copy of each of which is attached as an exhibit to this Current Report on Form 8-K and incorporated herein
by reference.
Item 3.02 Unregistered Sales of Equity Securities.
Pursuant
to the Purchase Agreement and the transactions contemplated thereby described in Item 1.01 above, the Company issued the Preferred
Shares and the Warrants to the Investors. The Company issued such securities in reliance on the exemption contained in Section
4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder.
Item 3.03 Material Modification to Rights of Security
Holders.
A total
of 1,200 shares of Series C Convertible Preferred Stock (the "
Series C Preferred Stock
") have been authorized
for issuance under the Certificate of Designation of Rights, Preferences and Privileges of Series C Convertible Preferred Stock
(the "
Certificate of Designation
"). The Company filed the Certificate of Designation with the Secretary of
State of the State of Delaware on March 7, 2014. The shares of Series C Preferred Stock have a stated value of $5,000 per share
and are initially convertible into shares of Common Stock at a price of $0.75 per share (subject to appropriate adjustment for
certain events, including stock splits, stock dividends, combinations, recapitalizations or other recapitalizations affecting
the Series C Preferred Stock). Under the Certificate of Designation, the holders of the Series C Preferred Stock have the following
rights, preferences and privileges:
The
Series C Preferred Stock may, at the option of the Investor, be converted at any time or from time to time into fully paid and
non-assessable shares of Common Stock at the conversion price in effect at the time of conversion. The number of shares into which
one share of Series C Preferred Stock shall be convertible is determined by dividing the stated value per share by the initial
Conversion Price.
The
Series C Preferred Stock will automatically be converted into Common Stock at the then applicable conversion Price upon the earliest
to occur of: (a) the written election of Investors holding at a majority of Series C Preferred Stock; (b) at the election of the
Company, the closing of a "Qualified Acquisition" (as defined in the Certificate of Designation); (c) at the election
of the Company, the closing of a bona-fide strategic financing by the Corporation yielding gross proceeds to the Corporation of
not less than $12 million (a "
Qualified Financing
"); or (d) at the election of the Company, the date on which
the Common Stock commences trading on a national securities exchange. Investors holding a majority of Series C Preferred Stock
will also have the right to convert the outstanding Series C Preferred Stock into such number or amount of the securities of the
Company that are issued upon the closing of a Qualified Financing that occurs on or prior to the one-year anniversary of the first
date following the filing of the Certificate of Designation on which the Company is current with respect to the filing of all
reports required to be filed by it pursuant to Sections 13 or 15(d) of the Exchange Act (other than Form 8-K reports) as have
a purchase price equal to the stated value of the outstanding shares of Series C Preferred Stock, plus any accrued and unpaid
dividends thereon.
On
any matter presented to the holders of Common Stock for their action or consideration, each holder of outstanding shares of Series
C Preferred Stock shall be entitled to vote together with the holders of Common Stock as a single class on an as-converted basis.
In addition, for as long as any shares of Series C Preferred Stock are outstanding, the Company shall not, without the affirmative
vote of Investors holding at least a majority of the Series C Preferred Stock: (a) alter or change adversely the powers, preferences
or rights given to the Series C Preferred Stock or alter or amend the Certificate of Designation; (b) authorize or create any
class of stock ranking senior to, or otherwise pari passu with, the Series C Preferred Stock; (c) amend its organizational documents
in any manner that adversely affects any rights of the Series C Preferred Stock; (d) increase the number of authorized shares
of Series C Preferred Stock; or (e) enter into any agreement with respect to any of the foregoing.
In the
event of any voluntary or involuntary liquidation or dissolution of the Company, before any payment shall be made to the holders
of Common Stock, the holders of shares of Series C Preferred Stock then outstanding shall be entitled to be paid an amount per
share of Series C Preferred Stock equal to the greater of (a) the stated value for such share of Series C Preferred Stock, plus
any dividends declared but unpaid thereon, or (b) the amount as would have been payable had such share of Series C Preferred Stock
been converted into Common Stock immediately prior to such liquidation or dissolution. The remaining funds shall be distributed
to the holders of Common Stock.
The
Company may not declare, pay or set aside any dividends on shares of any class or series of capital stock of the Company (other
than dividends on shares of Common Stock payable in shares of Common Stock) unless the holders of the Series C Preferred Stock
shall first receive, or simultaneously receive, an equal dividend on each outstanding share of Series C Preferred Stock.
Item 5.03 Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.
The
disclosures set forth in Items 1.01 and 3.03 of this Current Report on Form 8-K are hereby incorporated by reference into this
Item 5.03.
Item 8.01 Other Events.
Press Release
On March 11, 2014, the Company issued
a press release announcing that it had entered into, and consummated the transactions contemplated by, the Purchase Agreement.
A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Investor Presentation
On March 11, 2014, the Company presented
at the BIO-Europe Spring® 2014 partnering conference. A copy of the presentation is attached as Exhibit 99.2 to this Current
Report on Form 8-K and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
3.1
Certificate of Designation of Rights,
    Preferences and Privileges of Series C Convertible Preferred Stock.
4.1
Form of Common Stock Purchase Warrant.
10.1
Securities Purchase Agreement dated as of March 7, 2014 between
    and among the Company and each purchaser identified on the signature pages thereto.
99.1
Press release of Marina Biotech, Inc. dated March
    11, 2014.
99.2
Investor Presentation of Marina Biotech, Inc.
__________
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Marina Biotech, Inc.
March 10, 2014
By:
/s/ J. Michael French
Name:
J. Michael French
Title:
Chief Executive Officer
EXHIBIT INDEX
Exhibit No.
Description
3.1
Certificate of Designation of Rights,
    Preferences and Privileges of Series C Convertible Preferred Stock.
4.1
Form of Common Stock Purchase Warrant.
10.1
Securities Purchase Agreement dated as of March 7, 2014 between
    and among the Company and each purchaser identified on the signature pages thereto.
99.1
Press release of Marina Biotech, Inc. dated March 11, 2014.
99.2
Investor Presentation of Marina Biotech, Inc.
__________